News for Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences (ASMB) to participate in the Jefferies 2025 Global Healthcare Conference. CEO Jason Okazaki and Chief Medical Officer Dr. Anuj Gagg

**media[638490]**

”“ Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitor

Revenue: $9.4 million, surpassing the estimated $7.41 million for the quarter.Earnings Per Share (EPS): Reported at -$1.17, better than the estimated -$1.60.Ne

The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Revenue: $28.5 million for the year ended December 31, 2024, significantly surpassing the estimated annual revenue of $22.10 million, driven by collaboration w

”“ Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline ”“ ”“ Interim Phase 1b

Assembly Biosciences (ASMB) reports FY GAAP EPS of -$6.69, beating estimates by $0.18. Revenue surges 298.3% Y/Y to $28.52M. Shares rise 1.96%.

**media[572448]**

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Assembly Biosciences, Inc.

”“ Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 ”“ ”“ Biomarker of

On February 18, 2025, Gilead Sciences, Inc. executed a significant stock transaction involving Arcus Biosciences Inc (RCUS). The firm added 9,630,525 shares of

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a strategic transaction involving Assembly Biosciences Inc (ASMB), reducing its holdin

D.E. Shaw To Return Billions After Flagship Hedge Fund Gains 18% (Bloomberg) Two Sub-$100 Warren Buffett Stocks To Buy And Hold For Long-Term (Finbold) Bill Ackman’s Pershing Square Fund To De-List From Amsterdam Stock Exchange (Billboard.

The S&P 500 futures are down 19 points, the Nasdaq 100 futures are down 75 points, and the Dow Jones Industrial Average futures are down 139 points, indicating

Assembly Biosciences (ASMB) stock gains on interim data from a Phase 1 trial for its hepatitis B treatment ABI-4334 developed with Gilead (GILD). Read more here.

”“ ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed ”“ ”“ In the first 150 mg dose coho